Update in Asthma Management: A Narrative Review of Recent Advances, Challenges, and Future Directions

BACKGROUND: Asthma is a heterogeneous chronic respiratory disease with persistent morbidity and mortality despite effective therapies. The UK continues to report high asthma-related deaths, underscoring the need for improved care. OBJECTIVE: To review recent advances in asthma management, identify ongoing challenges, and outline future directions for clinical practice. METHODS: This narrative review integrates recent guideline updates (BTS/SIGN 2024, GINA 2024), audit data (NACAP), and emerging evidence on diagnostics, phenotype-driven therapy, and novel treatments. FINDINGS: Innovations include biomarker-guided phenotyping, anti-inflammatory reliever (AIR) therapy, biologics targeting Type 2 inflammation, and structured frameworks like A2BCD. Foundational care-such as adherence, inhaler technique, and self-management-remains essential. Systemic improvements, including virtual wards and the BTS Asthma4 bundle, enhance continuity of care. The NHS Green Agenda supports sustainable asthma practices. CONCLUSIONS: Asthma care is evolving toward personalised, integrated, and environmentally conscious approaches. Clinicians should combine precision therapies with system-level strategies to optimise outcomes.